Qian DZ - Search Results

1

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R. Qian DZ, et al. Clin Cancer Res. 2006 Jan 15;12(2):634-42. doi: 10.1158/1078-0432.CCR-05-1132. Clin Cancer Res. 2006. PMID: 16428510

2

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R. Qian DZ, et al. Cancer Res. 2004 Sep 15;64(18):6626-34. doi: 10.1158/0008-5472.CAN-04-0540. Cancer Res. 2004. PMID: 15374977

3

Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.

Wang XF, Qian DZ, Ren M, Kato Y, Wei Y, Zhang L, Fansler Z, Clark D, Nakanishi O, Pili R. Wang XF, et al. Among authors: qian dz. Clin Cancer Res. 2005 May 1;11(9):3535-42. doi: 10.1158/1078-0432.CCR-04-1092. Clin Cancer Res. 2005. PMID: 15867257

4

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha.

Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P, Pili R. Qian DZ, et al. Cancer Res. 2006 Sep 1;66(17):8814-21. doi: 10.1158/0008-5472.CAN-05-4598. Cancer Res. 2006. PMID: 16951198

5

Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.

Kato Y, Salumbides BC, Wang XF, Qian DZ, Williams S, Wei Y, Sanni TB, Atadja P, Pili R. Kato Y, et al. Among authors: qian dz. Mol Cancer Ther. 2007 Jan;6(1):70-81. doi: 10.1158/1535-7163.MCT-06-0125. Mol Cancer Ther. 2007. PMID: 17237267

6

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.

Qian DZ, Wei YF, Wang X, Kato Y, Cheng L, Pili R. Qian DZ, et al. Prostate. 2007 Aug 1;67(11):1182-93. doi: 10.1002/pros.20611. Prostate. 2007. PMID: 17520666

7

Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model.

Verheul HM, Hammers H, van Erp K, Wei Y, Sanni T, Salumbides B, Qian DZ, Yancopoulos GD, Pili R. Verheul HM, et al. Among authors: qian dz. Clin Cancer Res. 2007 Jul 15;13(14):4201-8. doi: 10.1158/1078-0432.CCR-06-2553. Clin Cancer Res. 2007. PMID: 17634549

8

Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.

Verheul HM, Salumbides B, Van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R. Verheul HM, et al. Among authors: qian dz. Clin Cancer Res. 2008 Jun 1;14(11):3589-97. doi: 10.1158/1078-0432.CCR-07-4306. Clin Cancer Res. 2008. PMID: 18519793

9

Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.

Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci MA, Rudek MA. Pili R, et al. Br J Cancer. 2012 Jan 3;106(1):77-84. doi: 10.1038/bjc.2011.527. Epub 2011 Dec 1. Br J Cancer. 2012. PMID: 22134508 Free PMC article. Clinical Trial.

10

In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.

Qian DZ, Ren M, Wei Y, Wang X, van de Geijn F, Rasmussen C, Nakanishi O, Sacchi N, Pili R. Qian DZ, et al. Prostate. 2005 Jun 15;64(1):20-8. doi: 10.1002/pros.20209. Prostate. 2005. PMID: 15651062

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42 results

Search Page

Filters